89bio Inc (ETNB)

$9.9499

-0.01

(-0.1%)▲

Market is closed - opens 8 PM, 07 Dec 2023

Insights on 89bio Inc

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 83.0% return, outperforming this stock by 58.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 83.4%

Performance

  • $9.70
    $10.24
    $9.95
    downward going graph

    2.51%

    Downside

    Day's Volatility :5.28%

    Upside

    2.84%

    downward going graph
  • $6.58
    $22.93
    $9.95
    downward going graph

    33.87%

    Downside

    52 Weeks Volatility :71.3%

    Upside

    56.61%

    downward going graph

Returns

Period89bio IncSector (Health Care)Index (Russel 2000)
3 Months
-42.99%
0.3%
0.0%
6 Months
-51.3%
1.7%
0.0%
1 Year
24.97%
-4.0%
-2.4%
3 Years
-62.72%
17.2%
-6.5%

Highlights

Market Capitalization
686.0M
Book Value
$5.42
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.8
Wall Street Target Price
32.44
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-25.61%
Return On Equity TTM
-44.97%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-135.3M
Diluted Eps TTM
-1.8
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.1
EPS Estimate Next Year
-2.56
EPS Estimate Current Quarter
-0.53
EPS Estimate Next Quarter
-0.54

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for 89bio Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
15
14
Hold
2
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 226.03%

Current $9.95
Target $32.44

Technicals Summary

Sell

Neutral

Buy

89bio Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
89bio Inc
89bio Inc
20.14%
-51.3%
24.97%
-62.72%
-52.12%
Moderna, Inc.
Moderna, Inc.
8.62%
-38.31%
-54.89%
-50.93%
320.86%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.38%
9.73%
9.82%
65.7%
115.07%
Novo Nordisk A/s
Novo Nordisk A/s
-1.43%
23.95%
58.41%
192.13%
336.59%
Seagen, Inc.
Seagen, Inc.
0.74%
10.42%
83.05%
20.41%
247.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.19%
7.19%
13.58%
55.97%
97.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
89bio Inc
89bio Inc
NA
NA
NA
-2.1
-0.45
-0.26
0.0
5.42
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
89bio Inc
89bio Inc
Buy
$686.0M
-52.12%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
320.86%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
115.07%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
336.59%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
247.89%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
97.18%
26.38
35.94%

Institutional Holdings

  • RA Capital Management, LLC

    15.09%

  • BlackRock Inc

    6.57%

  • State Street Corporation

    5.69%

  • HHG PLC

    5.33%

  • Vanguard Group Inc

    4.66%

  • Suvretta Capital Management, LLC

    3.56%

Corporate Announcements

  • 89bio Inc Earnings

    89bio Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.

Organization
89bio Inc
Employees
45
CEO
Mr. Rohan Palekar
Industry
Health Technology

Discover More

FAQs